Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
Type:
Grant
Filed:
July 24, 2008
Date of Patent:
August 20, 2013
Assignee:
Areta International S.R.L.
Inventors:
Riccardo Dolcetti, Massimo Guidoboni, Valli De Re, Daniela Gasparotto, Sonia Castiglioni, Maria Luisa Nolli
Abstract: This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGA1) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGA1 in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGA1 proteins.
Type:
Grant
Filed:
April 29, 2009
Date of Patent:
March 12, 2013
Assignee:
Areta International S.R.L.
Inventors:
Alfredo Fusco, Antonio Orlandi, Maria Luisa Nolli
Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
Type:
Application
Filed:
July 24, 2008
Publication date:
December 9, 2010
Applicant:
ARETA INTERNATIONAL S.r.l
Inventors:
Riccardo Dolcetti, Massimo Guidoboni, Valli De Re, Daniela Gasparotto, Sonia Castiglioni, Maria Luisa Nolli